

An Observational Study of Ckd with Anaemia in Tertiary Care Centre

Balaji Prasad Ramiseti¹, C. Yadavendra Reddy², P. Prudhvi³

¹Assistant Professor Department of Medicine ESICMCH Sanathnagar

²Professor Department of Medicine MRIMS Suraram

³Senior Resident Department of Medicine ESICMCH Sanathnagar

Received: 20-03-2023 / Revised: 11-04-2023 / Accepted: 05-05-2023

Corresponding author: Dr. P. Prudhvi

Conflict of interest: Nil

Abstract

Background: Iron deficiency anaemia is the leading cause of heart failure in ckd patients. this study was done to study the incidence of heart failure in diabetic kidney disease patients in government general hospital.

Materials and Methods: This Prospective Observational study was done for one year in tertiary care Hospital. A total of 100 cases male and female admitted for dialysis were studied based on inclusion and exclusion criteria. All patients were done routine investigations including iron studies, urine for microalbuminuria, 2decho and thoroughly elicited for history of diabetes. Patients below 12 years, pregnant women and patients with previous bleeding manifestations and heart ailments prior to onset of diabetes were excluded from the study. The study was carried out in all patients fulfilling the inclusion and exclusion criteria.

Results: A total of 100 patients 60 males and 40 females presented during the study period. Heart failure was more prevalent in diabetics in age group of 40-60 years. [>60 yrs. [25] >60 yrs [20], 20-40 yrs[8] out of these DM >5 YRS were 4 in 20-40 yrs, 16 in 40-60 yrs, 18 in >60 yrs. Microalbuminuria was present in 4 patients in 20-40 yrs, 16 patients in 40-60 yrs, 18 in >60 yrs age group with abnormal renal parameters. IDA was present in 12 patients in 20-40 yrs, 40 patients in 40-60 yrs, and 10 patients in >60 yrs.

Conclusion: It was Observed from the study that ida was leading cause of heart failure in patients with ckd. Even in those patients without prolonged dm history. anaemia was leading to heart failure with microalbuminuria.

Keywords: Iron Deficiency, Anaemia, CKD, Heart Failure, Microalbuminuria.

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

Introduction

Iron deficiency is a 'health-related condition in which iron availability is insufficient to meet the body's needs and which can be present with or without anaemia[1]. In chronic heart failure (CHF), iron deficiency is a recognized comorbidity affecting 37–61% of patients[2–5]. The causes of iron deficiency in the CHF setting can be multifactorial, arising from chronic inflammation, decreased iron

intake (poor nutrition and loss of appetite), decreased gastrointestinal (GI) iron absorption due to oedema, and increased GI blood loss (partially resulting from antiplatelet and anticoagulant drugs);[6,7]. Exercise intolerance and fatigue are defining features of patients with CHF. Studies have shown that iron deficiency, even before the onset of anaemia, can be particularly severe in

patients with CHF, aggravating the underlying disease and negatively impacting symptoms, quality of life (QoL), exercise capacity, and clinical outcomes, and has been associated which can be present with or without anaemia'. [1] In chronic heart failure (CHF), iron deficiency is a recognized co-morbidity with an increased risk of mortality of 40–60%. [2–4, 8–17]. In addition, iron deficiency has been shown to increase the risk of hospitalization in patients with CHF by two-fold [8]. Appropriate treatment of iron deficiency in CHF activation and the presence of pro-inflammatory cytokines resulting in a deficient production of erythropoietin and impaired utilisation of iron, as well as malnutrition, which is common in these patients; haemodilution also contributes to anaemia. Clinical guidelines and consensus documents define iron deficiency in patients with HF based on ferritin levels has been shown to alleviate symptoms and decrease hospitalizations for heart failure [10–15].

The 2016 European Society of Cardiology (ESC) guidelines for the diagnosis and treatment of acute and chronic heart failure recommend that all newly diagnosed patients with heart failure are tested for iron deficiency [18]. Chronic kidney disease and anaemia are common in heart failure (HF) and are associated with a worse prognosis in these patients. Iron deficiency is also common in patients with HF and increases the risk of morbidity and mortality, regardless of the presence or absence of anaemia. Anaemia is a common complication in heart failure (HF) patients and is associated with more symptoms, worse functional class, a higher rate of hospitalisation and greater mortality [19, 20]. In addition, changes in anaemia status during follow-up in patients with HF modify the risk of mortality [21]. The presence of chronic kidney disease (CKD) is also very common in this population, and the prevalence of HF

increases as the glomerular filtration rate decreases [22]. In addition, anaemia is more prevalent in patients with HF and CKD [23]. This complication is therefore emerging as a potentially modifiable and important factor in the treatment of chronic HF [19, 24]. The presence of CKD or anaemia are associated with increased morbidity and mortality in HF, and the interaction of a decreased glomerular filtration rate and low haemoglobin level on mortality are additional risk factors [25]. The causes of anaemia in HF include: iron deficiency, renal dysfunction and neurohormonal <100 µg/l or between 100–300 µg/l with transferrin saturation <20%. It is estimated that between 30% and 50% of patients with HF have iron deficiency. [26, 27] Iron deficiency may cause anaemia, but it also has a direct harmful effect on myocytes [26, 27].

Material and Methods

This prospective observational study was carried out on patients of Department of general Medicine at tertiary care hospital for one year. A total of 100 patients admitted for dialysis were studied.

Study Design: Prospective observational study

Study Location: This study was done in Department of Medicine at tertiary care Hospital.

Study Duration: August 2019 to November 2019.

Sample Size: 100 patients.

Sample size calculation: The subjects were taken from the patients admitted for dialysis based on inclusion and exclusion criteria.

Subjects & selection Method: The subjects were selected based on their iron profile and renal parameters with duration of diabetes after careful history based on inclusion and exclusion criteria.

Inclusion criteria:

1. Patients with abnormal renal parameters.
2. Either sex
3. Aged ≥ 12 years,
4. DM history > 5 years
5. Urine for microalbuminuria

Exclusion criteria:

1. Pregnant women;
2. Patients with abnormal bleeding manifestations.
3. Patients with onset of heart ailments prior to onset of diabetes.
4. Patients < 12 years.

Procedure methodology

All patients admitted were questioned regarding their age, h/o dm, heart ailments and were done special investigations like iron studies, urine for microalbuminuria, 2d echo depending on their condition.

Statistical Analysis

Data was analyzed using SPASS software and Microsoft word and excel have been used to generate graphs, figure etc.

Results

Of all the patients 40[40%] were males and 60[60%] were females with female preponderance.

The patients admitted with abnormal renal parameters were more in the age group 40-60 around 56[56%] followed by age group above 60 around 28[28%]. out of these patients after thorough history dm >5 years were more in age group 40-60[16], >60 yrs were [18], were about 4 in age group 20-40yrs. out of this microalbuminuria was positive in age group >60 years. iron deficiency anaemia was more in age groups 40-60 years[40]. heart failure was more in patients with age group 40-60 yrs[25].

In Table 1 there depiction of patients with ckd more in age group 40-60yrs.




Figure 1: Age group

In Figure 2 the patients with gender predisposition were depicted.




Figure 2: Gender Distribution

In Figure 3 the patients with DM >5 YEARS were depicted.




Figure 3

In this Figure 4 patients with microalbuminuria in ckd were depicted.




Figure 4

In Figure 5 depiction of IDA in CKD is depicted.




Figure 5: Symptoms Distribution

In table 6 heart failure in ckd is depicted.




Figure 6

Discussion

In all out of 100 cases 40[40%] were male and 60[60%] were female showing female preponderance. Among them patients with CKD were more in the age group of 40-60 yrs were 56[56%]. in our study we had patients with DM history >5 years were 16[2.8%] in age group 40-60yrs. out of these we had micro-albuminuria in 16[2.8%] patients in the same age group. out of the patients studied we had 40[40%] patients in age group 40-60 yrs who had iron deficiency anaemia. We assessed the patients with iron deficiency anaemia for ferritin levels to exclude diabetes cause for heart failure. in our observation we had 25[10%] as compared to 37% in Janskowska[28] et al study. patients with increased ferritin levels leading to heart

failure signifying iron deficiency anaemia as a leading cause for heart failure.

Conclusion

Iron deficiency alone, even in the absence of anaemia, is a common co-morbidity in patients with CHF. If left untreated, iron deficiency can account for poor clinical outcomes.

The article provides a practical example of the diagnosis and management of iron deficiency in a patient with HFrEF, demonstrating the application of the current ESC guidelines in a clinical context. Treatment with i.v. ferric carboxymaltose improves clinical symptoms (from NYHA III to NYHA I; i.e. exercise capacity and QoL) with no adverse events. Furthermore, i.v. ferric carboxymaltose could provide cost-

effective savings as there was less intervention, that is, no hospitalizations or decompensations. Despite a solid evidence base and guideline recommendation, iron deficiency currently remains underdiagnosed and undertreated.

The 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure recommend evaluating the iron status of all newly diagnosed CHF patients and consideration of i.v. ferric carboxymaltose for those patients with iron deficiency to alleviate CHF symptoms and improve exercise capacity and QoL.

References

1. Cappellini MD, Comin-Colet J, De Francisco A, Dignass A, Doehner W, Lam SP, Macdougall IC, Rogler G, Camaschella C, Kadir R, Kassebaum NJ, Spahn DR, Taher AT, Musallam KM. Iron deficiency across chronic inflammatory conditions: international expert opinion on definition, diagnosis, and management. *Am J Hematol* 2017; 92: 1068– 1078.
2. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJ, Anker SD, Ponikowski P. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. *Eur Heart J* 2010; 31: 1872– 1880.
3. Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, Lok DJ, Rosentryt P, Torrens A, Polonski L, van Veldhuisen DJ, van der Meer P, Jankowska EA. Iron deficiency in chronic heart failure: an international pooled analysis. *Am Heart J* 2013; 165: 575– 582.
4. Okonko DO, Mandal AK, Missouriis CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. *J Am CollCardiol* 2011; 58: 1241– 1251.
5. Peyrin-Biroulet L, Williet N, Cacoub P. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. *Am J Clin Nutr* 2015; 102: 1585– 1594.
6. Scholar Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. *Eur Heart J* 2013; 34: 816– 829.
7. McDonagh T, Macdougall IC. Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral? *Eur J Heart Fail* 2015; 17: 248– 262.
8. Toblli JE, Lombrana A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. *J Am CollCardiol* 2007; 50: 1657– 1665.
9. Avni T, Leibovici L, Gafter-Gvili A. Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis. *Eur J Heart Fail* 2012; 14: 423– 429.
10. Anker SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, Comin-Colet J, Ruschitzka F, Luscher TF, Arutyunov GP, Motro M, Mori C, Roubert B, Pocock SJ, Ponikowski P. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. *Eur J Heart Fail* 2018; 20: 125– 133.
11. Jankowska EA, Tkaczyszyn M, Suchocki T, Drozd M, von Haehling S, Doehner W, Banasiak W, Filippatos G, Anker SD, Ponikowski P. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. *Eur J Heart Fail* 2016; 18: 786– 795.

12. Enjuanes C, Bruguera J, Grau M, Cladellas M, Gonzalez G, Merono O, Moliner-Borja P, Verdu JM, Farre N, Comin-Colet J. Iron status in chronic heart failure: impact on symptoms, functional class and submaximal exercise capacity. *Rev EspCardiol (Engl Ed)* 2016; 69: 247– 255.
13. Anker SD, Comin CJ, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart RB, Pocock SJ, Poole-Wilson PA, Ponikowski P. Ferric carboxymaltose in patients with heart failure and iron deficiency. *N Engl J Med* 2009; 361: 2436– 2448.
14. van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Bohm M, Doletsky A, Voors AA, Macdougall IC, Anker SD, Roubert B, Zakin L, Cohen-Solal A. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. *Circulation* 2017; 136: 1374– 1383.
15. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. *Eur Heart J* 2015; 36: 657– 658.
16. Comin-Colet J, Enjuanes C, Gonzalez G, Torrens A, Cladellas M, Merono O, Ribas N, Ruiz S, Gomez M, Verdu JM, Bruguera J. Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. *Eur J Heart Fail* 2013; 15: 1164– 1172.
17. Enjuanes C, Klip IT, Bruguera J, Cladellas M, Ponikowski P, Banasiak W, van Veldhuisen DJ, van der MP, Jankowska EA, Comin-Colet J. Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study. *Int J Cardiol* 2014; 174: 268– 275.
18. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2016; 37: 2129– 2200.
19. H.F. Groenveld, J.L. Januzzi, K. Damman, J. van Wijngaarden, H.L. Hillege, D.J. van Veldhuisen, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. *J Am Coll Cardiol*, 2008;52: 818-827.
20. J.A. Ezekowitz, F.A. McAlister, P.W. Armstrong. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12065 patients with new-onset heart failure. *Circulation*, Medline. 2003; 107: 223-225.
21. C. Díez-López, J. Lupón, M. de Antonio, E. Zamora, M. Domingo, J. Santesmases, et al. Hemoglobin kinetics and long-term prognosis in heart failure. *Rev Esp Cardiol Engl Ed*, 2016;69: 820-826
22. S.M. Bagshaw, D.N. Cruz, N. Aspromonte, L. Daliento, F. Ronco, G. Sheinfeld, et al. Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI consensus conference. *Nephrol Dial Transpl*, 2010; 25: 1406-1416
23. A.S. Go, J. Yang, L.M. Ackerson, K. Lepper, S. Robbins, B.M. Massie, et al. Hemoglobin level, chronic kidney

- disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization. ANCHOR Study. Circulation, Medline. 2006;113: 2713-2723.
24. R.K. Spence. The economic burden of anemia in heart failure. Heart Fail Clin, 2010;6: 373-383
25. Al-Ahmad, W.M. Rand, G. Manjunath, M.A. Konstam, D.N. Salem, A.S. Levey, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol, Medline. 2001;38: 955-962.
26. E.A. Jankowska, S. von Haehling, S.D. Anker, I.C. Macdougall, P. Ponikowski. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J, 2013;34: 816-826.
27. Cohen-Solal, C. Leclercq, G. Deray, S. Lasocki, J.J. Zambrowski, A. Mebazaa, et al. Iron deficiency: an emerging therapeutic target in heart failure. Heart, 2014;100: 1014-1029
28. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja Banasiak W, Polonski L, Filippatos G, McMurray JJ, Anker SD, Ponikowski P. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010 Aug;31(15):1872-80.